Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- All Candidates from Nichiiren Fail to Obtain Seat in Upper House
July 26, 2010
- Iressa Doubles PFS in Japanese NSCLC Patients with Mutated EGFR
July 26, 2010
- Parliamentary Secretary for Health Shinya Adachi Reelected
July 26, 2010
- Kobayashi to Develop More Class 1 OTC Drugs
July 26, 2010
- Dr Fujii Regains Seat in Upper House
July 26, 2010
- JPA to Renew Its Efforts to Increase Members' Awareness of New OTC Drug Sales System
July 26, 2010
- Standardize Interpretation of 1980 Notification: Chuikyo
July 26, 2010
- Erbitux Associated with Fewer Severe Infusion Reactions in Japan
July 26, 2010
- Industry Criticized Again at Chuikyo Meeting
July 26, 2010
- Test for Predicting Efficacy of IFN Recommended for Approval as Advanced Technology
July 26, 2010
- Use of New Drugs Increasing in Cancer Therapy: CareNet
July 26, 2010
- Most Member Pharmacies Have Correctly Understood Significance of Premium: NPhA
July 26, 2010
- Nippon Chemiphar Aims at Sales of ¥30.0 Bil. with Generics in FY2012
July 26, 2010
- Interest Shown in Development of 3 More Unapproved Drugs
July 26, 2010
- Drug Market in Japan to Grow 3-6% in 2010-2014: IMS Japan
July 26, 2010
- Takeda Confident about Actos Data
July 26, 2010
- GL Published by Korosho for Evaluation of Oral Hypoglycemic Agents
July 19, 2010
- Astellas, Teva Reach Settlement Agreement on Vesicare Patent Lawsuit
July 19, 2010
- Merck to Develop Biosimilars: Dr Wiederrecht
July 19, 2010
- Some Diseases Can Be Prevented Only by Vaccines: Dr Sonobe
July 19, 2010
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…